These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 27028202

  • 1. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
    Saini L, Brandwein J, Turner R, Larratt L, Hamilton M, Peters A, Wu C, Zhu N, Patterson JM, Bolster L, Mant M, Ritchie B, Liew E, Ghosh S, Sandhu I.
    Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B, Aytac S, Balci YI, Unal S, Kuskonmaz B, Yetgin S, Gurgey A, Tuncer M, Gumruk F, Uckan D, Cetin M.
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [Abstract] [Full Text] [Related]

  • 3. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S.
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H, Tomizawa D, Tanaka S, Iwamoto S, Shimada A, Saito AM, Yamashita Y, Moritake H, Terui K, Taga T, Matsuo H, Kosaka Y, Koh K, Hosoi H, Kurosawa H, Isoyama K, Horibe K, Mizutani S, Adachi S.
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
    Qian SX, Wu HX, Hong M, Lu H, Xu W, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1577-81. PubMed ID: 20030951
    [Abstract] [Full Text] [Related]

  • 10. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A.
    Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
    [Abstract] [Full Text] [Related]

  • 11. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Westhus J, Noppeney R, Dührsen U, Hanoun M.
    Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Apr; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 16. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 17. [Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
    Wang LJ, Ding J, Zhu CY, Yang H, Wang HX, Jing Y, Yu L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):19-24. PubMed ID: 26913387
    [Abstract] [Full Text] [Related]

  • 18. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA.
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
    [Abstract] [Full Text] [Related]

  • 19. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
    Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D.
    J Clin Oncol; 2013 Sep 20; 31(27):3360-8. PubMed ID: 23940227
    [Abstract] [Full Text] [Related]

  • 20. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
    Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED.
    Leuk Res; 2006 Apr 20; 30(4):503-6. PubMed ID: 16303178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.